BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND SUZ12, CHET9, 23512, ENSG00000178691, Q15022, KIAA0160, JJAZ1 AND Prognosis
8 results:

  • 1. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
    Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
    Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
    Martinez-Baquero D; Sakhdari A; Mo H; Kim DH; Kanagal-Shamanna R; Li S; Young KH; O'Malley DP; Dogan A; Jain P; Wang ML; McDonnell TJ; Miranda RN; Vega F; Medeiros LJ; Ok CY
    Mod Pathol; 2021 Dec; 34(12):2183-2191. PubMed ID: 34376807
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
    Kaito S; Iwama A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.
    Kim SH; Kim SH; Yang WI; Kim SJ; Yoon SO
    Oncotarget; 2017 May; 8(19):31305-31317. PubMed ID: 28412742
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
    Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
    Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
    D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
    J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Aberrations of EZH2 in cancer.
    Chase A; Cross NC
    Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.